Colchicine: An old wine in a new bottle?

Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry

Volumn 12, Issue 1, 2013, Pages 14-23

  Roubille, François ^a,b,c   Kritikou, Ekaterini ^a   Busseuil, David ^a   Barrère Lemaire, Stéphanie ^b,c   Tardif, Jean Claude ^a  

^a MONTREAL HEART INSTITUTE   (Canada)

^b MONTPELLIER UNIVERSITY HOSPITAL   (France)

^c UNIV MONTPELLIER   (France)

Author keywords

Cardiovascular diseases; Colchicine; Gout; Inflammation; Pericardial diseases; Pericarditis; Tubulin

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; AZITHROMYCIN; CLARITHROMYCIN; COLCHICINE; CRYOPYRIN; CYCLOOXYGENASE 2; CYCLOSPORIN; CYTOCHROME P450 3A4; DIRITHROMYCIN; ERYTHROMYCIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 18 RECEPTOR; JOSAMYCIN; KETOCONAZOLE; MIDECAMYCIN; MULTIDRUG RESISTANCE PROTEIN 1; OPIATE; PLACEBO; PRISTINAMYCIN; PROSTAGLANDIN E2; PROTEINASE INHIBITOR; SPIRAMYCIN; TELITHROMYCIN; THROMBOXANE A2; TIEMONIUM IODIDE; TROLEANDOMYCIN; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VERAPAMIL;

ABDOMINAL PAIN; ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; ADULT RESPIRATORY DISTRESS SYNDROME; AMINO ACID COMPOSITION; AMYLOIDOSIS; ANEMIA; ARTHRITIS; AZOOSPERMIA; BEHCET DISEASE; BONE MARROW SUPPRESSION; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CELL MIGRATION; CELL MOTILITY; CHONDROCALCINOSIS; CREATININE CLEARANCE; DERMATITIS HERPETIFORMIS; DIARRHEA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; FAMILIAL MEDITERRANEAN FEVER; GASTROINTESTINAL DISEASE; GOUT; HUMAN; HYPOCALCEMIA; KIDNEY DYSFUNCTION; LEUKOCYTOCLASTIC VASCULITIS; LEUKOPENIA; LIVER DYSFUNCTION; LIVER METABOLISM; LOW DRUG DOSE; MICROTUBULE ASSEMBLY; MULTICENTER STUDY (TOPIC); NAUSEA; NECROTIZING ARTERITIS; NONHUMAN; PERICARDIAL DISEASE; PERICARDITIS; PRIMARY BILIARY CIRRHOSIS; PROTEIN INTERACTION; PSORIASIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSING POLYCHONDRITIS; RESTENOSIS; REVIEW; RHABDOMYOLYSIS; SEPSIS; SIDE EFFECT; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; CARDIOVASCULAR DISEASES; COLCHICINE; FEMALE; GOUT; HUMANS; MALE; MIDDLE AGED; PERICARDITIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84875826374     PISSN: 18715230     EISSN: 1875614X     Source Type: Journal    
DOI: 10.2174/1871523011312010004     Document Type: Review

References (96)

1. Rodnan, G.P.; Benedek, T.G. The early history of antirheumatic drugs. Arthritis Rheum, 1970, 13 (2), 145-65.
2. Roberts, W.N.; Liang, M.H.; Stern, S.H. Colchicine in acute gout. Reassessment of risks and benefits. JAMA, 1987, 257 (14), 1920-1922.
3. Wallace, S.L. Colchicum: The panacea. Bull. N Y Acad. Med., 1973, 49 (2), 130-135.
4. Pelletier, P. S, C. J. Ann. Chim. Phys. 1820.
5. Wallace, S. Benjamin Franklin and the introduction of colchicum into the United States. Bull. Hist. Med., 1968, 42 (4), 312-320.
6. Dustin, P. The centennial of the discovery of the antimitotic properties of colchicine. Rev. Med. Brux., 1989, 10 (9), 385-390.
7. Bhat, A.; Naguwa, S.M.; Cheema, G.S.; Gershwin, M.E. Colchicine revisited. Anns. N. Y. Acad. Sci., 2009, 1173, 766-773.
8. Weisenberg, R.C.; Borisy, G.G.; Taylor, E.W. The colchicinebinding protein of mammalian brain and its relation to microtubules. Biochemistry, 1968, 7 (12), 4466-4479.
9. Adelman, M.R.; Borisy, G.G.; Shelanski, M.L.; Weisenberg, R.C.; Taylor, E.W. Cytoplasmic filaments and tubules. Fed. Proc., 1968, 27 (5), 1186-1193.
10. Shelanski, M.L.; Taylor, E.W. Properties of the protein subunit of central-pair and outer-doublet microtubules of sea urchin flagella. J. Cell Bbiol., 1968, 38 (2), 304-315.
11. Mohri, H. Amino-acid composition of "Tubulin" constituting microtubules of sperm flagella. Nature, 1968, 217 (5133), 1053-1054.
12. Ravelli, R.B.; Gigant, B.; Curmi, P.A.; Jourdain, I.; Lachkar, S.; Sobel, A.; Knossow, M. Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. Nature, 2004, 428 (6979), 198-202.
13. Matsukawa, A.; Yoshimura, T.; Maeda, T.; Takahashi, T.; Ohkawara, S.; Yoshinaga, M. Analysis of the cytokine network among tumor necrosis factor alpha, interleukin-1beta, interleukin-8, and interleukin-1 receptor antagonist in monosodium urate crystalinduced rabbit arthritis. Lab. Investig. J. Tech. Methods Pathol., 1998, 78 (5), 559-569.
14. Pope, R.M.; Tschopp, J. The role of interleukin-1 and the inflammasome in gout: Implications for therapy. Arthritis Rheumat., 2007, 56(10), 3183-3188.
15. Martinon, F.; Petrilli, V.; Mayor, A.; Tardivel, A.; Tschopp, J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature, 2006, 440 (7081), 237-241.
16. Cronstein, B.N.; Molad, Y.; Reibman, J.; Balakhane, E.; Levin, R. I.; Weissmann, G. Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils. J. Clin. Investig., 1995, 96 (2), 994-1002.
17. Marques-da-Silva, C.; Chaves, M.M.; Castro, N.G.; Coutinho-Silva, R.; Guimaraes, M.Z. Colchicine inhibits cationic dye uptake induced by ATP in P2X2 and P2X7 receptor-expressing cells: implications for its therapeutic action. Brit. J. Pharmacol., 2011, 163 (5), 912-926.
18. Ferrua, B.; Manie, S.; Doglio, A.; Shaw, A.; Sonthonnax, S.; Limouse, M.; Schaffar, L. Stimulation of human interleukin 1 production and specific mRNA expression by microtubuledisrupting drugs. Cellular Immunol., 1990, 131 (2), 391-397.
19. Cerquaglia, C.; Diaco, M.; Nucera, G.; La Regina, M.; Montalto, M.; Manna, R. Pharmacological and clinical basis of treatment of Familial Mediterranean Fever (FMF) with colchicine or analogues: An update. Curr. Drug Targets. Inflamm. Allergy 2005, 4 (1), 117-124.
20. Sabouraud, A.; Rochdi, M.; Urtizberea, M.; Christen, M.O.; Achtert, G.; Scherrmann, J.M. Pharmacokinetics of colchicine: A review of experimental and clinical data. Zeitschrift fur Gastroenterologie, 1992, 30 (Suppl 1), 35-39.
21. Cocco, G.; Chu, D.C.; Pandolfi, S. Colchicine in clinical medicine. A guide for internists. Eur. J. Intern. Med., 2010, 21 (6), 503-508.
22. Wallace, S.L.; Ertel, N.H. Plasma levels of colchicine after oral administration of a single dose. Metabolism: Clin. Exp., 1973, 22 (5), 749-753.
23. Achtert, G.; Scherrmann, J.M.; Christen, M.O. Pharmacokinetics/bioavailability of colchicine in healthy male volunteers. Euro. j. Drug Metab. Ph., 1989, 14 (4), 317-322.
24. Ferron, G.M.; Rochdi, M.; Jusko, W.J.; Scherrmann, J.M. Oral absorption characteristics and pharmacokinetics of colchicine in healthy volunteers after single and multiple doses. J. Clin. Pharmacol., 1996, 36 (10), 874-883.
25. Tateishi, T.; Soucek, P.; Caraco, Y.; Guengerich, F.P.; Wood, A.J. Colchicine biotransformation by human liver microsomes. Identification of CYP3A4 as the major isoform responsible for colchicine demethylation. Biochem. Pharmacol., 1997, 53 (1), 111-116.
26. Finkelstein, Y.; Aks, S.E.; Hutson, J.R.; Juurlink, D.N.; Nguyen, P.; Dubnov-Raz, G.; Pollak, U.; Koren, G.; Bentur, Y. Colchicine poisoning: The dark side of an ancient drug. Clin. Toxicol., 2010, 48 (5), 407-414.
27. Ben-Chetrit, E.; Scherrmann, J.M.; Levy, M. Colchicine in breast milk of patients with familial Mediterranean fever. Arthritis Rheum., 1996, 39 (7), 1213-7.
28. Wallace, S.L.; Omokoku, B.; Ertel, N.H. Colchicine plasma levels. Implications as to pharmacology and mechanism of action. Am. J. Med., 1970, 48 (4), 443-448.
29. Fordham, J.N.; Kirwan, J.; Cason, J.; Currey, H.L. Prolonged reduction in polymorphonuclear adhesion following oral colchicine. Ann. Rheum. Dis., 1981, 40 (6), 605-608.
30. Maisch, B.; Seferovic, P.M.; Ristic, A.D.; Erbel, R.; Rienmuller, R.; Adler, Y.; Tomkowski, W.Z.; Thiene, G.; Yacoub, M.H. Task Force on the, D. Management of Pricardial Diseases of the European Society of, C., Guidelines on the diagnosis and management of pericardial diseases executive summary; The Task force on the diagnosis and management of pericardial diseases of the European society of cardiology. Euro. Heart J., 2004, 25 (7), 587-610.
31. Imazio, M.; Bobbio, M.; Cecchi, E.; Demarie, D.; Demichelis, B.; Pomari, F.; Moratti, M.; Gaschino, G.; Giammaria, M.; Ghisio, A.; Belli, R.; Trinchero, R. Colchicine in addition to conventional therapy for acute pericarditis: results of the COlchicine for acute PEricarditis (COPE) trial. Circulation, 2005, 112 (13), 2012-2016.
32. Imazio, M.; Bobbio, M.; Cecchi, E.; Demarie, D.; Pomari, F.; Moratti, M.; Ghisio, A.; Belli, R.; Trinchero, R. Colchicine as firstchoice therapy for recurrent pericarditis: Results of the CORE (COlchicine for REcurrent pericarditis) trial. Arch, InternMed, 2005, 165 (17), 1987-91.
33. Imazio, M.; Brucato, A.; Cemin, R.; Ferrua, S.; Belli, R.; Maestroni, S.; Trinchero, R.; Spodick, D.H.; Adler, Y.; Investigators, C. Colchicine for recurrent pericarditis (CORP): A randomized trial. Ann. Intern. Med., 2011, 155 (7), 409-14.
34. Imazio, M.; Brucato, A.; Rovere, M.E.; Gandino, A.; Cemin, R.; Ferrua, S.; Maestroni, S.; Zingarelli, E.; Barosi, A.; Simon, C.; Sansone, F.; Patrini, D.; Vitali, E.; Belli, R.; Ferrazzi, P.; Trinchero, R.; Spodick, D.H.; Adler, Y. Colchicine prevents early postoperative pericardial and pleural effusions. Am. Heart J., 2011, 162 (3), 527-532 e1.
35. Meurin, P.; Tabet, J.Y. Colchicine in acute pericarditis: A new standard? Arch. Cardiovasc. Dis., 2011, 104 (8-9), 425-427.
36. Imazio, M.; Brucato, A.; Ferrazzi, P.; Rovere, M. E.; Gandino, A.; Cemin, R.; Ferrua, S.; Belli, R.; Maestroni, S.; Simon, C.; Zingarelli, E.; Barosi, A.; Sansone, F.; Patrini, D.; Vitali, E.; Trinchero, R.; Spodick, D.H.; Adler, Y.; Investigators, C. Colchicine reduces postoperative atrial fibrillation: Results of the Colchicine for the Prevention of the Postpericardiotomy Syndrome (COPPS) atrial fibrillation substudy. Circulation, 2011, 124 (21), 2290-2295.
37. Adler, Y.; Finkelstein, Y.; Guindo, J.; Rodriguez de la Serna, A.; Shoenfeld, Y.; Bayes-Genis, A.; Sagie, A.; Bayes de Luna, A.; Spodick, D.H. Colchicine treatment for recurrent pericarditis. A decade of experience. Circulation, 1998, 97 (21), 2183-2185.
38. Adler, Y.; Spodick, D.H.; Shabetai, R.; Brucato, A. Can colchicine prevent recurrence of new-onset acute pericarditis? Nat. Clin. Pract. Cardiovasc. Med., 2006, 3 (2), 78-79.
39. Flather, M.; Collinson, J. First line treatment with colchicine reduced recurrent pericarditis. Evidence-Based Med., 2006, 11 (2), 44.
40. Imazio, M.; Brucato, A.; Trinchero, R.; Spodick, D.; Adler, Y. Colchicine for pericarditis: Hype or hope? Euro. Heart J., 2009, 30 (5), 532-539.
41. Wojcicki, J.; Hinek, A.; Jaworska, M.; Samochowiec, L. The effect of colchicine on the development of experimental atherosclerosis in rabbits. Polish J. Pharmacol. Pharm., 1986, 38 (4), 343-348.
42. Nidorf, M.; Thompson, P.L. Effect of colchicine (0.5 mg twice daily) on high-sensitivity C-reactive protein independent of aspirin and atorvastatin in patients with stable coronary artery disease. Am. J. Cardiol., 2007, 99 (6), 805-7.
43. Terkeltaub, R.A.; Furst, D.E.; Bennett, K.; Kook, K.A.; Crockett, R.S.; Davis, M.W. High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum., 2010, 62 (4), 1060-8.
44. Terkeltaub, R.A.; Furst, D.E.; Digiacinto, J.L.; Kook, K.A.; Davis, M.W. Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P-glycoprotein inhibitors. Arthritis Rheum., 2011, 63 (8), 2226-2237.
45. Curiel, R.V.; Guzman, N.J. Challenges associated with the management of gouty arthritis in patients with chronic kidney disease: A systematic review. Semin. Arthritis Rheum., 2012.
46. Marwah, R.K. Comorbidities in gouty arthritis. J. investig. med. 2011, 59 (8), 1211-1220.
47. Fravel, M.A.; Ernst, M.E. Management of gout in the older adult. Am. J. Geriatric Pharmacother., 2011, 9 (5), 271-285.
48. Stamp, L.K.; Jordan, S. The challenges of gout management in the elderly. Drugs Aging, 2011, 28 (8), 591-603.
49. Mailhes, J.B.; Yuan, Z.P. Differential sensitivity of mouse oocytes to colchicine-induced aneuploidy. Environ. Mol. Mutagen., 1987, 10 (2), 183-188.
50. Mijatovic, V.; Hompes, P.G.; Wouters, M.G. Familial Mediterranean fever and its implications for fertility and pregnancy. Eur. J. Obstetrics, Gynecol. Reproduc. Biol., 2003, 108 (2), 171-176.
51. Ben-Chetrit, E.; Levy, M. Reproductive system in familial Mediterranean fever: An overview. Ann. Rheum. Dis., 2003, 62 (10), 916-919.
52. Zemer, D.; Livneh, A.; Danon, Y.L.; Pras, M.; Sohar, E. Long-term colchicine treatment in children with familial Mediterranean fever. Arthritis Rheum., 1991, 34 (8), 973-977.
53. Ben-Chetrit, E.; Levy, M. Colchicine prophylaxis in familial Mediterranean fever: reappraisal after 15 years. Semin. Arthritis Rheum., 1991, 20 (4), 241-246.
54. Ben-Chetrit, E.; Ben-Chetrit, A.; Berkun, Y.; Ben-Chetrit, E. Pregnancy outcomes in women with familial Mediterranean fever receiving colchicine: Is amniocentesis justified? Arthritis Care Res., 2010, 62 (2), 143-148.
55. Zayed, A.; Nabil, H.; State, O.; Badawy, A. Subfertility in women with familial Mediterranean fever. J. Obst. Gynaecol. Res., 2012. 38(10), 1240-1244.
56. Ehrenfeld, M.; Brzezinski, A.; Levy, M.; Eliakim, M. Fertility and obstetric history in patients with familial Mediterranean fever on long-term colchicine therapy. Brit. J. Obst. Gynaecol., 1987, 94 (12), 1186-1191.
57. Li, G.P.; White, K.L.; Aston, K.I.; Bunch, T.D.; Hicks, B.; Liu, Y.; Sessions, B.R. Colcemid-treatment of heifer oocytes enhances nuclear transfer embryonic development, establishment of pregnancy and development to term. Mol. Reproduc. Dev., 2009, 76 (7), 620-628.
58. Imazio, M.; Brucato, A.; Rampello, S.; Armellino, F.; Trinchero, R.; Spodick, D.H.; Adler, Y. Management of pericardial diseases during pregnancy. J. Cardiovasc. Med., 2010, 11 (8), 557-562.
59. Merlin, H.E. Azoospermia caused by colchicine--a case report. Fertil. Steril., 1972, 23 (3), 180-181.
60. Kirchin, V.S.; Southgate, H.J.; Beard, R.C. Colchicine: An unusual cause of reversible azoospermia. BJU int., 1999, 83 (1), 156.
61. Ben-Chetrit, E.; Backenroth, R.; Haimov-Kochman, R.; Pizov, G. Azoospermia in familial Mediterranean fever patients: the role of colchicine and amyloidosis. Ann. Rheum. Dis., 1998, 57 (4), 259-260.
62. Bremner, W.J.; Paulsen, C.A., Colchicine and testicular function in man. N. Engl. J. Med., 1976, 294 (25), 1384-5.
63. Laborde, J.V.H., A. Le colchique et la colchicine. Paris. G. Steinheil, 1887.
64. Brouardel, P. Les empoisonnements criminels et accidentels. Ed Baillières, Paris. 1902.
65. Finkelstein, Y.; Aks, S.E.; Hutson, J.R.; Juurlink, D.N.; Nguyen, P.; Dubnov-Raz, G.; Pollak, U.; Koren, G.; Bentur, Y. Colchicine poisoning: the dark side of an ancient drug. Clin. Toxicol.,2010, 48 (5), 407-414.
66. Ozdemir, R.; Bayrakci, B.; Teksam, O. Fatal poisoning in children: acute colchicine intoxication and new treatment approaches. Clin. Toxicol., 2011, 49 (8), 739-743.
67. Nagesh, K.R.; Menezes, R.G.; Rastogi, P.; Naik, N.R.; Rasquinha, J.M.; Senthilkumaran, S.; Fazil, A. Suicidal plant poisoning with Colchicum autumnale. J. Forensic Legal Med., 2011, 18 (6), 285-7.
68. van Heyningen, C.; Watson, I.D. Troponin for prediction of cardiovascular collapse in acute colchicine overdose. EMJ, 2005, 22 (8), 599-600.
69. Mullins, M.E.; Carrico, E.A.; Horowitz, B.Z. Fatal cardiovascular collapse following acute colchicine ingestion. Journal of toxicology. Clin. Toxicol., 2000, 38 (1), 51-54.
70. Milne, S.T.; Meek, P.D. Fatal colchicine overdose: report of a case and review of the literature. Am. J. Emer. Med., 1998, 16 (6), 603-608.
71. Mullins, M.; Cannarozzi, A.A.; Bailey, T.C.; Ranganathan, P. Unrecognized fatalities related to colchicine in hospitalized patients. Clin. Toxicol., 2011, 49 (7), 648-652.
72. Hood, R.L. Colchicine poisoning. J. Emerg. Med., 1994, 12 (2), 171-177.
73. Baud, F.J.; Sabouraud, A.; Vicaut, E.; Taboulet, P.; Lang, J.; Bismuth, C.; Rouzioux, J.M.; Scherrmann, J.M. Brief report: treatment of severe colchicine overdose with colchicine-specific Fab fragments. N. Eng. J. Med., 1995, 332(10), 642-645.
74. Flanagan, R.J.; Jones, A.L. Fab antibody fragments: Some applications in clinical toxicology. Drug safety: Intern. J. Med. Toxicol. Drug Exp., 2004, 27 (14), 1115-1133.
75. Grody, W.W.; Getzug, T., Colchicine's other indication--effect of FDA action. N. Eng. J. Med., 2010, 363 (23), 2267-2268.
76. Kesselheim, A.S.; Solomon, D.H. Incentives for drug development--the curious case of colchicine. N. Eng. J. Med., 2010, 362 (22), 2045-2047.
77. Wertheimer, A.I.; Davis, M.W.; Lauterio, T.J. A new perspective on the pharmacoeconomics of colchicine. Curr. Med. Res. Opin. 2011, 27 (5), 931-937.
78. Shen, Q.; Wang, Y.; Zhang, Y. Improvement of colchicine oral bioavailability by incorporating eugenol in the nanoemulsion as an oil excipient and enhancer. Intern. J. Nanomed., 2011, 6, 1237-1243.
79. Lai, M.J.; Kuo, C.C.; Yeh, T.K.; Hsieh, H.P.; Chen, L.T.; Pan, W. Y.; Hsu, K. Y.; Chang, J.Y.; Liou, J. P. Synthesis and structureactivity relationships of 1-benzyl-4,5,6-trimethoxyindoles as a novel class of potent antimitotic agents. ChemMedChem., 2009, 4 (4), 588-593.
80. Raju, N.C.; Yi, Q.; Nidorf, M.; Fagel, N.D.; Hiralal, R.; Eikelboom, J. W. Effect of colchicine compared with placebo on high sensitivity C-reactive protein in patients with acute coronary syndrome or acute stroke: A pilot randomized controlled trial. J. Thromb. Thrombolysis., 2012, 33 (1), 88-94.
81. Wright, D.G.; Wolff, S.M.; Fauci, A.S.; Alling, D.W. Efficacy of intermittent colchicine therapy in familial Mediterranean fever. Ann. Intern. Med., 1977, 86 (2), 162-165.
82. Masuda, K.; Nakajima, A.; Urayama, A.; Nakae, K.; Kogure, M.; Inaba, G. Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behcet's disease. Lancet, 1989, 1 (8647), 1093-1096.
83. Nuki, G. Colchicine: Its mechanism of action and efficacy in crystal-induced inflammation. Curr. Rheumatol. Reports., 2008, 10 (3), 218-227.
84. Kaplan, M.M.; Alling, D.W.; Zimmerman, H.J.; Wolfe, H.J.; Sepersky, R.A.; Hirsch, G.S.; Elta, G.H.; Glick, K.A.; Eagen, K.A. A prospective trial of colchicine for primary biliary cirrhosis. N. Eng. J. Med., 1986, 315 (23), 1448-1454.
85. Gong, Y.; Gluud, C. Colchicine for primary biliary cirrhosis: A Cochrane Hepato-Biliary Group systematic review of randomized clinical trials. Am. J. Gastroenterol., 2005, 100 (8), 1876-1885.
86. McKendry, R.J.; Kraag, G.; Seigel, S.; Al-Awadhi, A. Therapeutic value of colchicine in the treatment of patients with psoriatic arthritis. Ann. Rheum. Dis., 1993, 52 (11), 826-828.
87. Kyle, R.A.; Gertz, M.A.; Greipp, P.R.; Witzig, T.E.; Lust, J.A.; Lacy, M.Q.; Therneau, T. M. A trial of three regimens for primary amyloidosis: Colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N. Eng. J. Med., 1997, 336 (17), 1202-1207.
88. Arik, N.; Yuksel, H.; Adam, B.; Akpolat, T.; Ozdemir, O. May colchicine therapy be of value in the prevention of dialysis amyloidosis? Nephron, 1996, 73 (2), 365-366.
89. Klein, I. Colchicine stimulates the rate of contraction of heart cells in culture. Cardiovasc. Res., 1983, 17 (8), 459-465.
90. Nath, K.; Shay, J.W.; Bollon, A.P. Relationship between dibutyryl cyclic AMP and microtubule organization in contracting heart muscle cells. Proc. Natl. Acad. Sci. USA, 1978, 75 (1), 319-323.
91. Crie, J.S.; Ord, J.M.; Wakeland, J.R.; Wildenthal, K. Inhibition of cardiac proteolysis by colchicine. Selective effects on degradation of protein subclasses. Biochem. J., 1983, 210 (1), 63-71.
92. Limas, C.J. Myocardial colchicine-binding proteins: Possible relation to DNA synthesis initiation. J. Mol. Cellular Cardiol., 1979, 11 (11), 1137-1150.
93. van der Zee, H.H.; Prens, E.P. The anti-inflammatory drug colchicine lacks efficacy in hidradenitis suppurativa. Dermatology, 2011, 223 (2), 169-173.
94. Altenburg, A.; Abdel-Naser, M.B.; Seeber, H.; Abdallah, M.; Zouboulis, C.C. Practical aspects of management of recurrent aphthous stomatitis. J. Euro. Acad. Dermatol. Venereol., 2007, 21 (8), 1019-1026.
95. Pietrogrande, M.; De Vita, S.; Zignego, A. L.; Pioltelli, P.; Sansonno, D.; Sollima, S.; Atzeni, F.; Saccardo, F.; Quartuccio, L.; Bruno, S.; Bruno, R.; Campanini, M.; Candela, M.; Castelnovo, L.; Gabrielli, A.; Gaeta, G. B.; Marson, P.; Mascia, M. T.; Mazzaro, C.; Mazzotta, F.; Meroni, P.; Montecucco, C.; Ossi, E.; Piccinino, F.; Prati, D.; Puoti, M.; Riboldi, P.; Riva, A.; Roccatello, D.; Sagnelli, E.; Scaini, P.; Scarpato, S.; Sinico, R.; Taliani, G.; Tavoni, A.; Bonacci, E.; Renoldi, P.; Filippini, D.; Sarzi-Puttini, P.; Ferri, C.; Monti, G.; Galli, M. Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients. Autoimmunity Rev., 2011, 10 (8), 444-454.
96. Muntoni, S.; Rojkind, M.; Muntoni, S. Colchicine reduces procollagen III and increases pseudocholinesterase in chronic liver disease. World J. Gastroenterol., 2010, 16 (23), 2889-2894.